{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This randomized controlled trial evaluated echocardiographic data from the Placement of Aortic Transcatheter Valves (PARTNER) 1 Trial."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomized to TAVR or surgical aortic valve replacement (SAVR) in PARTNER 1A (TAVR, n=321; SAVR, n=313) and TAVR or medical treatment in PARTNER 1B (TAVR, n=165)."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included severe aortic stenosis, and the study was conducted across multiple centers."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized to TAVR or surgical aortic valve replacement (SAVR) in PARTNER 1A (TAVR, n=321; SAVR, n=313) and TAVR or medical treatment in PARTNER 1B (TAVR, n=165)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was death or reintervention for aortic valve structural indications, assessed over a median follow-up of 3.1 years."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not specified."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Participants were randomized to TAVR or surgical aortic valve replacement (SAVR) in PARTNER 1A (TAVR, n=321; SAVR, n=313) and TAVR or medical treatment in PARTNER 1B (TAVR, n=165)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 2795 patients (mean age 84.5 years, 47% female), 424 TAVR and 49 SAVR patients had 5-year echocardiogram data."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "TAVR showed early favorable hemodynamic changes, with a decrease of \u22122.9 mm Hg in aortic valve mean gradient, an increase of 0.028 in Doppler velocity index, and an increase of 0.09 cm\u00b2 in effective orifice area, with stability over time."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00530894."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}